Invitrogen Names Two Executives in Bioinformatics; New Vice President and Director of Research and Development Share Company's Commitment to Bioinformatics Capability.Business Editors/Health/Medical Writers BIOWIRE2K CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 19, 2004 Invitrogen Corp. (Nasdaq: IVGN), a provider of essential life science technologies for disease research and drug discovery, today announced that it has named Michael Stapleton, Ph.D., general manager and vice president of its bioinformatics business. Additionally, the company named Vivien Bonazzi, Ph.D., director, research and development, bioinformatics. Both positions exemplify Invitrogen's commitment to making bioinformatics an integral part of its solution set for life science research. "As we move toward the creation of a complete operating system operating system (OS) Software that controls the operation of a computer, directs the input and output of data, keeps track of files, and controls the processing of computer programs. for disease research and drug discovery, we realize that bioinformatics capabilities are essential to researchers who are striving to gain the maximum value and understanding from the experiments they perform," explained Gregory T. Lucier, president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Invitrogen Corp. "Bioinformatics is a very important part of the larger picture for our efforts in improving the human condition." Stapleton brings to Invitrogen extensive experience as a software executive. For more than a decade he served in a variety of scientific and leadership roles with Accelrys Inc. As executive vice president and chief operating officer Chief Operating Officer (COO) The officer of a firm responsible for day-to-day management, usually the president or an executive vice-president. he was responsible for creating Accelrys through the mergers of Molecular Simulations with Oxford Molecular, Genetics Computer Group, Synopsys Scientific Systems and Synomics, all leading providers of computational chemistry Computational chemistry is a branch of chemistry that uses computers to assist in solving chemical problems. It uses the results of theoretical chemistry, incorporated into efficient computer programs, to calculate the structures and properties of molecules and solids. , cheminformatics and bioinformatics solutions. Prior to Accelrys, Stapleton worked in industry at British Petroleum Research, and also held a post doctoral position in the School of Chemical Engineering at Cornell University Cornell University, mainly at Ithaca, N.Y.; with land-grant, state, and private support; coeducational; chartered 1865, opened 1868. It was named for Ezra Cornell, who donated $500,000 and a tract of land. With the help of state senator Andrew D. . Stapleton holds a bachelor's degree in chemistry and master's and doctorate degrees in chemical physics from Southampton University in the United Kingdom. "Invitrogen offers a wealth of opportunity for creating new solutions to enable researchers to produce more meaningful results from their experiments," commented Stapleton. "I am looking forward to further driving the consolidation of wet and dry lab processes that will create more value for the company's traditional product lines and more ability for scientists working on the puzzles of disease." Bonazzi will lead the worldwide research and development effort in bioinformatics, driving the creation of new software tools. She brings to Invitrogen a long history of bioinformatics expertise, most recently serving as director of product development and scientific management at Celera Genomics in Rockville, Md. Bonazzi also held positions at Celera such as director of the company's Gene Discovery Group and has served in bioinformatics roles with The Institute for Genomic Research and the Howard Florey Institute The Howard Florey Institute, previously known as the Howard Florey Institute of Experimental Physiology and Medicine, is a world-renowned Australian medical and research institute that undertakes clinical and applied research into treatments to combat brain and mind of Experimental Physiology and Medicine in Melbourne, Australia. She holds a bachelor's degree in applied science from the University of Canberra The University of Canberra is an Australian university, located in Canberra, the capital of Australia. It is the second largest university in Canberra. The University was one of nine Australian universities recognised by the Australian government in 2006 for high achievement in in Australia, as well as master's and doctorate degrees in molecular pharmacology pharmacology, study of the changes produced in living animals by chemical substances, especially the actions of drugs, substances used to treat disease. Systematic investigation of the effects of drugs based on animal experimentation and the use of isolated and from the University of Melbourne
In 2006, Times Higher Education Supplement ranked the University of Melbourne 22nd in the world. Because of the drop in ranking, University of Melbourne is currently behind four Asian universities - Beijing University, . Speaking on the need to continually create new technologies to expand researchers' understanding of the volumes of information they regularly produce, Bonazzi explained, "As a team at Invitrogen, we are committed to developing leading-edge software tools that build upon the pedigree of Vector NTI NTI NewTech Infosystems (software company, Irvine, California) NTI Nuclear Threat Initiative NTI National Transit Institute (New Brunswick, New Jersey) NTI Nunavut Tunngavik Incorporated (TM) to help scientists find new meaning in their results and deliver the biologicals that will make the therapies of the future." Both Stapleton and Bonazzi began work at Invitrogen on Jan. 19. Stapleton reports to Daryl Faulkner, senior vice president, global business segments, while Bonazzi reports to Claude Benchimol, Ph.D., senior vice president, research and development. About Invitrogen Invitrogen Corp. (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery and commercial bio-production. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics Noun 1. functional genomics - the branch of genomics that determines the biological function of the genes and their products genomics - the branch of genetics that studies organisms in terms of their genomes (their full DNA sequences) , proteomics, bio-informatics and cell biology Cell biology The study of the activities, functions, properties, and structures of cells. Cells were discovered in the middle of the seventeenth century after the microscope was invented. -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen has headquarters in Carlsbad, Calif., and conducts business in more than 70 countries around the world. The company globally employs approximately 3,000 scientists and other professionals. For more information about Invitrogen, visit the company's Web site at www.invitrogen.com. Safe Harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. Statement Certain statements contained in this press release are considered "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Invitrogen's commitment to making bioinformatics an integral part of its solution set for life science research; 2) Invitrogen's creation of a complete operating system for disease research and drug discovery ; 3) Stapleton's appointment will further drive the consolidation of wet lab and dry lab processes; 4) Consolidation of processes will create more value for Invitrogen's existing product lines; 5) Bonazzi's appointment will drive the creation of new software tools; 6) Invitrogen will create new software tools based on the pedigree of Vector NTI. Potential risks and uncertainties include, but are not limited to, the risks: a) that Invitrogen may keep bioinformatics separate from its traditional solution set; b) that Invitrogen may decide to continue to offer individual solutions for researchers rather than an operating system; c) Stapleton's experience may not make a significant impact on Invitrogen's bioinformatics business; d) that Invitrogen's product line values will not be affected by consolidation with bioinformatics tools; e) that Bonazzi's appointment will not have an effect on the introduction of new software tools; and f) that Invitrogen will create tools that diverge diverge - If a series of approximations to some value get progressively further from it then the series is said to diverge. The reduction of some term under some evaluation strategy diverges if it does not reach a normal form after a finite number of reductions. from the standard that Vector NTI has established, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion